A total of 505 patients underwent randomization: 250 were assigned to the device group and 255 to the control group. At 24 months, the rate of first or recurrent hospitalization for heart failure ...

Moderate-to-severe MR (RR 3.2, 95% CI 1.9–5.2, P = 0.0001) was an independent predictor of HF. Conclusion: The mortality and morbidity of patients with LV dysfunction and FMR remain high despite ...

Mitral transcatheter edge-to-edge repair (M-TEER) reduced cardiovascular death and heart failure (HF)-related hospitalizations with improved health status in patients with HF and moderate to ...

Background: There are insufficient data regarding how to deal with moderate aortic valve (AV) dysfunction during rheumatic mitral valve (MV) surgery. In this study, the clinical outcomes of ...

- Led by Rahul Sharma MBBS, FRACP, and Colleagues, Findings Presented Today at the TCT Conference - - Key Findings Demonstrate Patients with Moderate-to-Severe Mitral Regurgitation are 3 Times ...

US-based 4C Medical has enrolled the first patients in a pivotal trial for its transcatheter mitral valve replacement (TMVR) device, the AltaValve System, for treating moderate or severe mitral ...

LONG BEACH, Calif. — Patients with heart failure who also experienced mitral regurgitation saw a doubling of their creatinine, according to data presented here.“Reduced kidney function is an ...

It includes 450 patients determined to be unsuitable for open heart surgery or transcatheter edge-to-edge repair, divided into two non-randomized cohorts: one for patients with moderate/severe ...

PARIS--(BUSINESS WIRE)--HighLife SAS, a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate ...